Department of Medical Biotechnology and Translational Medicine, University of Milan, Via Saldini 50, 20133, Milan, Italy.
National Research Council, CNR-SCITEC, Via G. Fantoli 16/15, 20138, Milan, Italy.
Glycoconj J. 2021 Aug;38(4):475-490. doi: 10.1007/s10719-021-09988-6. Epub 2021 Mar 17.
The increased phenomenon of antimicrobial resistance and the slow pace of development of new antibiotics are at the base of a global health concern regarding microbial infections. Antibiotic resistance kills an estimated 700,000 people each year worldwide, and this number is expected to increase dramatically if efforts are not made to develop new drugs or alternative containment strategies. Increased vaccination coverage, improved sanitation or sustained implementation of infection control measures are among the possible areas of action. Indeed, vaccination is one of the most effective tools of preventing infections. Starting from 1970s polysaccharide-based vaccines against Meningococcus, Pneumococcus and Haemophilus influenzae type b have been licensed, and provided effective protection for population. However, the development of safe and effective vaccines for infectious diseases with broad coverage remains a major challenge in global public health. In this scenario, nanosystems are receiving attention as alternative delivery systems to improve vaccine efficacy and immunogenicity. In this report, we provide an overview of current applications of glyconanomaterials as alternative platforms in the development of new vaccine candidates. In particular, we will focus on nanoparticle platforms, used to induce the activation of the immune system through the multivalent-displacement of saccharide antigens.
抗菌药物耐药性的增加和新抗生素开发的缓慢步伐是全球微生物感染相关健康问题的根源。抗生素耐药性每年在全球导致约 70 万人死亡,如果不努力开发新药物或替代遏制策略,这一数字预计将大幅增加。增加疫苗接种覆盖率、改善卫生条件或持续实施感染控制措施是可能采取的行动领域之一。事实上,疫苗接种是预防感染最有效的手段之一。自 20 世纪 70 年代以来,针对脑膜炎球菌、肺炎球菌和乙型流感嗜血杆菌的多糖疫苗已获得许可,并为人群提供了有效保护。然而,开发具有广泛覆盖范围的安全有效的传染病疫苗仍然是全球公共卫生的主要挑战。在这种情况下,纳米系统作为改善疫苗效力和免疫原性的替代递药系统受到关注。在本报告中,我们概述了糖基纳米材料作为新型疫苗候选物开发替代平台的当前应用。特别是,我们将重点介绍纳米颗粒平台,这些平台通过糖抗原的多价置换来诱导免疫系统的激活。